Leylah M. Drusbosky

Reply by Authors

Sam S. Chang, Karim Chamie, Charles A. Seabury, MARK L. GONZALGO et autres

us (code pays fourni par la source)

Reply by Authors

Sam S. Chang, Karim Chamie, Charles A. Seabury, MARK L. GONZALGO et autres

us (code pays fourni par la source)

Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG in BCG-Unresponsive NMIBC with Carcinoma In Situ ± Papillary Disease

Sam S. Chang, Karim Chamie, Charles A. Seabury, MARK L. GONZALGO et autres

PURPOSE: We report long-term follow-up on participants in the QUILT-3.032 study in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) ± papillary disease using nogapendekin alfa inbakicept (NAI) approved by the FDA (ANKTIVA) in combination with BCG. MATERIALS AND METHODS: Participants …

us (code pays fourni par la source)

151TiP Phase III trial ResQ201A of NAI plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy

D.A. Breadner, Andreas Nicholas Saltos, E.S. Santos, W. Iams et autres

Immune checkpoint inhibitors (ICIs) are approved for use as monotherapy and in combination with chemotherapy in advanced NSCLC. Unfortunately, most patients experience progressive disease with limited treatment options, warranting better options following progression. Prior phase II studies have demonstrated the potential for …

gb, us (code pays fourni par la source)

Supplementary Figure S5 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres

Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.

Supplementary Table S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres

Baseline Patient Characteristics – Cohort A

Supplementary Figure S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres

Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.

Supplementary Figure S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres

A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior …

Supplementary Figure S3 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres

Survival outcomes according to KEAP1 (A), SMARCA4 (B), and CDKN2A (C) co-mutation status in Cohorts A and B.

Supplementary Table S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres

Baseline Patient Characteristics – Overall Cohort

Supplementary Figure S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres

Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.

Supplementary Table S5 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres

Multivariable analysis - overall survival